Abstract 50P
Background
Breast Cancer is the most diagnosed cancer type worldwide and the second leading cause of cancer-related deaths among women. Anti-HER2 treatment has shifted the treatment paradigm of HER2-positive tumors. Historically, only breast cancer patients with HER2 IHC score of 3+ or with HER2 gene (FISH) amplification have benefited from anti-HER2 agents. However, emerging evidence suggests that even a minimal amplification of HER2 may significantly impact response to therapy and prognosis. This led to the introduction of the new concept of HER2-low breast cancers. Our retrospective analysis aims to unveil the impact of HER2 low expression on the response to neoadjuvant chemotherapy (NACT) in non-metastatic HER2-negative breast cancers.
Methods
All patients’ profiles with non-metastatic, HER2-negative breast cancers who received neo-adjuvant chemotherapy and underwent surgery between the 1st of January 2018 and the 30th of August 2022 were retrospectively reviewed. Patients were stratified into HER2-low and HER2-negative groups based on IHC score and FISH amplification. To compare the two study groups, patients’ response was clinically evaluated using surgical pathology reports. The primary endpoint was the response to NACT reported as the objective response rate (ORR) of HER2-low and HER2-negative tumors.
Results
Out of 262 patients, 236 patients had a response. Among the responders, 32 patients (14%) in the HER2-low group had a complete response compared to 4 patients (14%) in the HER2-negative group, OR 0.7 (95% CI:0.2 – 3), p-value= 0.6. While 132 patients (57%) and 17 patients (59%) had a partial response in the HER2-low and HER2-negative groups respectively, OR 0.7 (95% CI:0.2 – 2), p-value= 0.5. Across both groups, more patients with hormone-positive tumors had a response compared to hormone-negative tumors (p-value=0.01).
Conclusions
Preliminary results did not show any statistically significant impact of HER2 low expression on neoadjuvant chemotherapy response. Nonetheless, statistical significance was observed relative to hormone expression, in accordance with the published literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center, Hamad Medical Corporation.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract